AISAP CARDIO
FDA-cleared AI-powered cardiac ultrasound diagnostic platform for point-of-care
Software · Cloud SaaSCompany source
Company profile
About Aisap
AISAP is a healthcare AI company that has developed an FDA-cleared platform for point-of-care ultrasound (POCUS) diagnostics, with a primary focus on cardiac imaging and structural heart disease detection. The company's flagship product, POCUS OS, is an AI operating system that works with any POCUS device to deliver expert-level diagnostic results instantly at the point of care. AISAP's technology combines state-of-the-art AI capabilities with clinical expertise to transform the daily interface between physician and patient, making advanced cardiac diagnostics accessible to a wider range of healthcare providers. The platform addresses critical healthcare challenges including reducing hospital length of stay, shortening diagnostic turnaround times, enabling early detection of structural heart disease, and avoiding unnecessary patient transfers. AISAP's AI-powered interpretation provides objective, clinically relevant cardiac and valvular measurements that enhance confidence for both novice and experienced physicians performing cardiac ultrasound examinations. AISAP serves diverse healthcare settings including academic and large hospitals, community and rural hospitals, urgent care centers, cardiology clinics, primary care practices, and screening programs. The company has established partnerships with leading health systems including Sheba Medical Center, Stony Brook Medicine, Inova Health System, and Cardiology Consultants of Philadelphia. With research collaborations at top medical institutions and deployment across multiple countries including recent expansion into Africa, AISAP is working to democratize access to expert-level cardiac diagnostics globally.
Company description Aisap official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Aisap?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Aortic stenosis
- Cardiac pathologies
- Heart failure
- Structural heart disease
- Valvular disease
Who it serves
- Academic hospitals
- Cardiology clinics
- Community hospitals
- Concierge medicine
- Large hospitals
- Primary care practices
- Rural hospitals
- Screening programs
- Urgent care centers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsAfrica (Ghana mentioned) · International · Israel · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance for CARDIO AI-powered ultrasound platform; Strategic partnership with Cardiology Consultants of Philadelphia; Named one of world's most innovative companies for 2025; Launch of AI-based cardiac diagnostics initiative in Africa; Company relocation to Boston; Enterprise-wide implementation at Sheba Medical Center
Partnerships
Recorded partners
- Amavita Heart and Vascular Health
- Cardiology Consultants of Philadelphia
- Crozer Chester Medical Center
- Inova Health System
- MPcheck
- Peachtree POCUS
- Sheba Medical Center
- Soffer Health Institute
- Stony Brook Medicine
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
POCUS OS
AI operating system for any POCUS device
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Artificial Intelligence-Enhanced Cardiac Point-of-Care Ultrasound: A Prospective Single-Arm Study.Mayo Clinic proceedings. Digital health · Jun 1, 2026
Cross-sectional evaluation of cardiovascular biological age using point-of-care ultrasound.European heart journal. Digital health · Apr 1, 2026
Deep learning for atrioventricular regurgitation diagnosis: an external validation study.European heart journal. Digital health · Sep 1, 2025
AI assisted focused cardiac ultrasound in preventive cardiology - a perspective.NPJ cardiovascular health · Jun 26, 2025
Artificial Intelligence Assessment of Biological Age From Transthoracic Echocardiography: Discrepancies with Chronologic Age Predict Significant Excess Mortality.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · Aug 1, 2024
Clinical validation
Clinical-trial records
Reliability of Artificial Intelligence (AI)-Augmented Point-of-care Cardiac Ultrasound in the Hands of InternistsNCT05455541 · Mentioned · UNKNOWN
Prospective Acquisition of Cardiac Ultrasound Images at the Point of CareNCT05631977 · Sponsor · COMPLETED
Regulatory
Regulatory records
AISAP Cardio V1.0K234141 · 510k · Aug 1, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reduced length of stay
Enables timely discharge and reduces hospital crowding
Shortened turnaround time
Rapid, expert-level results instantly at point of care
Early disease detection
Identifies structural heart disease early in asymptomatic participants
Avoided patient transfers
Enables bedside diagnosis without need for transfer to imaging centers
Improved workflow efficiency
Enhanced provider throughput and clinical decision-making speed
Sheba Medical Center
Enterprise-wide implementation of AI-powered POCUS for early cardiac disease detection in screening programs and acute care
Reduced observation time and freed capacity for more acute cases; enabled early identification of structural heart disease in asymptomatic participants
Crozer Chester Medical Center
Implementation of AI-powered cardiac POCUS in hospital setting
Amavita Heart and Vascular Health
Early detection of aortic stenosis and structural heart disease for timely interventions
Dramatically improved early detection of structural heart disease; improved outcomes and lowered healthcare costs
Cardiology Consultants of Philadelphia (CCP)
Strategic partnership for cardiac diagnostics
Inova Schar Heart and Vascular, Inova Health System
Integration of AI-powered cardiac POCUS into acute care settings
Enhanced clinical oversight, improved workflow efficiency, and more efficient reliable bedside decisions
MPcheck
Early identification of structural heart disease in asymptomatic participants through screening programs
Enabled early identification of structural heart disease in asymptomatic participants
Soffer Health Institute
Implementation across primary care and cardiovascular offices for point-of-care decision-making
Improved efficiency, speed, and clinical decision-making; enhanced provider throughput and patient experience; noticeable gains in productivity and overall quality of care
Stony Brook Medicine
Enabling physicians to quickly and accurately diagnose structural heart disease and heart failure at bedside
Earlier detection and treatment with better patient outcomes
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Aisap
Recent articles published on Aisap's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.